

## REVIEW ARTICLE

## Open Access

# Hormonal contraception in women with migraine: is progestogen-only contraception a better choice?

Rossella E Nappi<sup>1,2,5\*</sup>, Gabriele S Merki-Feld<sup>3</sup>, Erica Terreno<sup>1,2</sup>, Alice Pellegrielli<sup>1,2</sup> and Michele Viana<sup>4</sup>**Abstract**

A significant number of women with migraine has to face the choice of reliable hormonal contraception during their fertile life. Combined hormonal contraceptives (CHCs) may be used in the majority of women with headache and migraine. However, they carry a small, but significant vascular risk, especially in migraine with aura (MA) and, eventually in migraine without aura (MO) with additional risk factors for stroke (smoking, hypertension, diabetes, hyperlipidemia and thrombophilia, age over 35 years). Guidelines recommend progestogen-only contraception as an alternative safer option because it does not seem to be associated with an increased risk of venous thromboembolism (VTE) and ischemic stroke.

Potentially, the maintenance of stable estrogen level by the administration of progestins in ovulation inhibiting dosages may have a positive influence of nociceptive threshold in women with migraine. Preliminary evidences based on headache diaries in migraineurs suggest that the progestin-only pill containing desogestrel 75 µg has a positive effect on the course of both MA and MO in the majority of women, reducing the number of days with migraine, the number of analgesics and the intensity of associated symptoms. Further prospective trials have to be performed to confirm that progestogen-only contraception may be a better option for the management of both migraine and birth control. Differences between MA and MO should also be taken into account in further studies.

**Keywords:** Migraine with aura (MA); Migraine without aura (MO); Combined hormonal contraceptives (CHCs); Combined oral contraceptives (COCs); Progestogen-only contraception; Desogestrel-only pill; Venous thromboembolism (VTE); Stroke

**Introduction**

Migraine is a disabling headache, characterized by moderate to severe head pain, usually accompanied by nausea, photophobia, phonophobia and osmophobia (migraine without aura, MO). In about 30% of patients migraine attacks are preceded by transient focal neurologic symptoms which are called aura (migraine with aura, MA). Migraine has a high socio-economical impact. In fact during migraine attacks most migraineurs reported severe impairment or the need of the bed rest and almost 40% of migraine patients have five or more headache days monthly [1]. The Global Burden of Disease survey 2010

(GBD) recently published showed that migraine is the seventh highest cause of disability in the world [2].

**Review**

In the last few years significant advance in the field of reversible hormonal methods has been achieved in order to maximize the benefits and to minimize the risks.

We believe it is relevant for clinical practice to briefly review in here potential vascular risks according to the category of migraine, with and without aura, and to the type of hormonal contraceptive option.

**Epidemiology of migraine and combined hormonal contraceptive (CHC) use**

Migraine affects about 18% of women and 6% of men in USA and Western Europe [3,4] and its cumulative lifetime prevalence is 43% in women and 18% in men [5]. It is then

\* Correspondence: [renappi@tin.it](mailto:renappi@tin.it)

<sup>1</sup>Research Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, IRCCS S. Matteo Foundation, Pavia, Italy

<sup>2</sup>Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Pavia, Italy

Full list of author information is available at the end of the article

mostly a female disorder, that it is active in particular during the fertile period of the women's life with a peak of prevalence in their 20s and 30s [6]. The reproductive life is characterized by the need of reliable and convenient methods of contraception. Among the several forms of contraceptives available, hormonal contraceptives are the most popular reversible method, both in USA and Europe and the "Pill" is the most used [7-9]. Low dose [20 to 30 µg ethinyl estradiol (EE2) per day] combined hormonal contraceptives (CHCs) have become the method of choice and the availability of new progestins (third- and fourth-generation) has allowed to achieve non-contraceptive benefits in comparison to older progestins (second-generation) [10]. CHCs are available in several regimens and routes of administration (oral, transdermal vaginal) in the attempt to improve tolerability, adherence and convenience of use [11]. Moreover, two new CHCs containing natural estradiol (E2), instead of EE2, have been introduced to increase safety and future developments are ongoing [12]. Interestingly, many gynecological conditions that are comorbid with migraine can be treated with CHCs. This enhances the likelihood of their use in migraine population [13]. The prescription of CHCs may have different effects on migraine with not univocal results because of many methodological limitations (diverse hormonal combinations, variable research settings, retrospective and/or cross-sectional designs, lack of a clear phenotyping of the headache according to IHS criteria, inadequate duration of observation) [14-16]. Historically, combined oral contraceptive (COCs) is the category best studied in migraineurs with an aggravation of migraine reported in 18-50% of cases, an improvement in 3-35% and no change in 39-65% [17]. A more recent cross-sectional study on a large population found that migraine is significantly associated with COCs assumption. Yet because of the design of the study it is not possible to define a causal relationship between exposure and disease [18]. Analysis on the different effect of the COCs on the two forms of migraine revealed that MA worsen more (56.4%) than MO (25.3%) [19]. Furthermore, women can present MA for the first time during the initiation of COCs [20]. During the last decade, a specific "window" of vulnerability triggered by the 7 days free hormone interval has been identified and the definition of hormonally-associated headaches (exogenous hormone-induced headache and estrogen-withdrawal headache) encompasses several patho-physiological mechanisms which are likely to explain nociceptive threshold in women [21,22]. Strategies to minimize estrogen withdrawal at the time of expected bleeding or to stabilize circulating estrogen at lower concentration include, respectively, 1) to use transdermal E2 during the free interval of hormonal contraception [22] or to shorten the interval from 7 to 4 and even to 2 days [23,24]; 2) to administer low dose COCs in

extended/flexible regimens [25] or to use extended vaginal contraception [26].

Very recently, Mac Gregor [27] reviewed the effects of currently available contraceptive methods in the context of the risks and benefits for women with migraine and non-migraine headaches and concluded that for the majority of women with headache and migraine, the choice of contraception is unrestricted. Indeed, the contraceptive method is unlikely to have an impact on headache, whereas migraine deserves accurate diagnosis and recognition of the impact of different methods on such condition.

#### **Vascular risks associated with CHCs and migraine**

MA, and to a lesser extent also MO, may increase vascular risk, especially the risk for ischemic stroke in younger women [27-30]. Moreover, evidences that need to be corroborated by further studies suggest an association between MA and cardiac events, intracerebral hemorrhage, retinal vasculopathy and mortality [31]. Even though the association between migraine and stroke appears to be independent of other cardiovascular risk factors [32], the presence of some risk factors, such as smoking and/or COCs use or their combination, further increase risk [33]. MA is associated with a twofold increased risk of ischemic stroke but the absolute risk associated with CHC use is very low in healthy young women with no additional risk factors and mostly related to the estrogen dose [34]. In spite of the considerable advances in terms of safety and tolerability of CHCs in migraine sufferers [13], their use is still questioned especially in women with additional risk factors for stroke, including, smoking, hypertension, diabetes, hyperlipidemia and thrombophilia, age over 35 years [35]. New evidences [36-38] have warned clinicians on the use of CHCs and the risk of venous thromboembolism (VTE) which is likely to be dependent on the type of the progestin [RR 1.6-2.4 by using third- and fourth-generation CHCs (namely, desogestrel, gestodene norgestimate and drospirenone, respectively) in comparison with those containing LNG (second-generation)] and the total estrogenicity of CHCs [39,40]. Even new routes (transdermal patch and vaginal ring) seem to be associated with an increased VTE risk, but data are contradictory [41-43]. Indeed, according to a statement very recently released [44] many factors contribute to VTE risk (e.g. age, duration of use, weight, family history) which makes epidemiological studies vulnerable to bias and confounders. In addition, the decision-making process should take into account not only the small VTE risk (absolute risk depending on the background prevalence rate between 2 to 8 per 10,000 users per year [45]) of the contraceptive method but also other elements such as efficacy, tolerability, additional health benefits, and acceptability which have to be discussed with the individual woman. In any case, it

is essential to follow the appropriate guidelines by avoiding the prescription of CHCs to women at elevated risk for VTE. In the context of migraine and CHCs use, it is very important to remember that the World Health Organization Medical Eligibility Criteria for Contraceptive Use stated that MA at any age is an absolute contraindication to the use of COCs (WHO Category 4) [46]. The US/WHO MEC is more restrictive than the UK/WHO MEC as regard to MO, rating CHCs as a category 4 for any migraineur over age 35 [47]. That being so, the personal risk assessment should guide the prescription of CHCs in selected conditions. When there is the sole need of contraception, without the added benefits of a peculiar hormonal compound and/or combination, CHCs with the lower vascular risk or alternative methods for birth control should be considered.

#### **Progestogen-only contraception: a class on its own**

The progestin component of hormonal contraceptives accounts for most of their contraceptive effects (inhibition of ovulation, suppression of endometrial activity, thickening of cervical mucus). Progestin-only methods includes pills (the pill most used in Europe contains low doses of desogestrel), injectables [depot Medroxyprogesteroneacetate (DMPA)], implants (the most recent long-acting reversible contraception contains Etonogestrel single-rod implant for at least 3 years), and intrauterine devices (levonorgestrel for at least 5 years) [48]. By providing effective and reversible contraception, progestin-only contraception has many noncontraceptive health benefits including improvement in dysmenorrhea, menorrhagia, premenstrual syndrome, and anemia [49]. Indeed, there is a general reduction of the amount of menstrual bleeding but cycle control may be erratic, a feature that may influence acceptability [50-52]. Progestin-only methods are appropriate for women who cannot or should not take CHCs because they have some contraindications to estrogen use and therefore display a higher risk of VTE [35,36]. The progestogen-only contraception is a safe alternative to CHCs and the avoidance of the estrogen component has many advantages not only for breastfeeding women but also for women with vascular diseases or risk factors for stroke [46,47]. The use of progestin-only contraception is not associated with an increased risk of VTE compared with non-users of hormonal contraception [53]. In addition, progestin-only pills, injectables, or implants are not associated with increased risk of ischemic stroke according to a recent metanalysis (OR 0.96; 95% CI: 0.70-1.31) [54]. Since the 1-year prevalence rates for migraine in women are 11% for MO and 5% for MA, respectively [55], there is potentially a high number of women in whom CHCs may be contraindicated according to WHO guidelines and progestogen-only contraception may be safely used [35,36].

#### **Evidence of progestogen-only contraception in women with migraine**

Given the evidence that progestogen-only contraception is a safer option for women with migraine, the main question is whether such contraceptive choice may influence the course of both MA and MO and offer a better management of the disease. Indeed, even though the excess risk of death for a woman taking modern CHCs is 1 in 100,000, which is much lower than the risk of everyday activities such as cycling [56], there is a biological plausibility that in women with migraine should be wiser to use an estrogen-free containing contraception to avoid any potential vascular risk. Two recent very large epidemiologic studies [36,57] reported the association between CHC and progestogen-only methods and cardiovascular risk, thrombo-embolic risk and stroke. Whereas no increased risk for deep venous thrombosis, myocardial infarction and thrombotic stroke was found for the progestogen-only methods, the risk were two-sixfold elevated in CHC users. The role of progesterone/progestins in the pathophysiology of migraine has been overshadowed by Somerville's early observations that it was the prevention of estrogen but not of progesterone withdrawal in the late phase of the cycle to be able to prevent the occurrence of migraine attacks [58,59]. Indeed, at variance with the influence of estrogens upon the cerebral structures implicated in the pathophysiology of migraine [60], cyclic variations in progestin levels were not related to migrainous headaches, but they rather seem to be protective. Progesterone apparently attenuates trigemino-vascular nociception [61] and its receptors are localized in areas of the central nervous system, which are involved in neuronal excitability and neurotransmitter synthesis release and transport [62]. It has been shown that progesterone can antagonize neuronal estrogenic effects by downregulating estrogen receptors [63]. Whereas estrogen peak decrease the threshold for cortical spreading depression (CSD), the neurobiological event underlying MA, estrogen withdrawal increased the susceptibility to CSD in an animal model [64]. Therefore, the maintenance of low estrogen levels and the avoidance of estrogen withdrawal by the administration of progestins in ovulation inhibiting dosages might decrease cortical excitability. Indeed, progestogen-only contraception has a continuous administration, without the hormone-free interval, and does not induce withdrawal stabilizing circulating estrogens, but some fluctuations according to different preparations may still occur [65]. Clinical data are scarce and no comparative studies with progestogen-only contraceptives and placebo or COCs are available in the literature [27]. Diagnoses are often inaccurate, without distinction between headache and migraine, and headache is reported in contraceptive progestin implant users as a potential cause of discontinuation [66]. Similarly, there is an increase in

headache, but not migraine, reported over time with both norethisterone enanthate and, especially with depot medroxyprogesterone acetate [67]. Anecdotally, migraine is more likely to improve in women who achieve amenorrhea [68]. In a large, cross-sectional, population-based study in Norway of 13944 women, a significant association between CHC and headaches, but no significant association between progestin-only pills and migraine (OR 1.3, 95% CI: 0.9–1.8) was found but the number of users was small [18]. To date two diary-based studies pilot studies on the effect of desogestrel 75 µg on migraine have been published [69,70]. Such oral daily pill inhibits ovulation and the dose allows the ovary to synthesize stable amounts of estrogen which are relevant for wellbeing and bone density [71]. The first study included thirty women with MA [69]. The use of desogestrel 75 µg resulted in a significant reduction in MA attacks and in the duration of aura symptoms, already after three months of observation. Interestingly, the beneficial effect of desogestrel 75 µg on visual and other neurological symptoms of aura was significantly present only in those women in whom MA onset was related to previous COCs treatment. These findings suggest that the reduction in estrogen levels may be relevant to the amelioration of MA, but do not exclude a direct effect of the progestin on CSD. The second study on the effect of desogestrel 75 µg included women with MA (n°=6) and with MO (n°=32) and evaluated migraine days, pain score and pain medication [70]. An improvement of each parameter was observed during 3 months use of desogestrel 75 µg in comparison to a three months pretreatment interval. A subanalyses of the effect on 32 women with MO revealed significant improvements in number of migraine days, pain medication and pain intensity. The mean number of migraine attacks at baseline was higher in comparison to that in the study of Nappi et al. [69], indicating that also very severe migraineurs might profit from such a progestin-only contraception. Chronic migraineurs often develop medication overuse headaches with severe limitation of their quality of life. The reduction of pain medication by progestin-only contraception is an interesting approach and it should be studied further. Indeed, there is a broad variation in the intensity of improvement with a reduction in migraine frequency ranging from 20% and 100% [70]. No indicators to identify those women who will profit from desogestrel 75 µg could be ascertained. On the other hand, there were few dropouts of women experiencing more migraine after starting contraception with this progestin in both studies, indicating that progestins can also deteriorate migraine in few cases.

A very recent study investigating the changes of quality of life in migraineurs 3 months after initiation of the progestagen-only pill desogestrel 75 µg demonstrates a highly significant reduction in Midas Score and Midas

grades [72]. However, clinical experience with desogestrel 75 µg in migraineurs further shows that during the initial 4 weeks migraine frequency can raise slightly before headaches improve. This information has to be mentioned and discussed during counseling.

In summary, the potential advantages of using progestogen-only contraception in women with migraine are the following:

- 1) Continuous use
- 2) Absence of estrogen peak
- 3) No influence on threshold for cortical spreading depression (CSD)
- 4) No evidence of increase in cardiovascular, stroke and thrombo-embolic risk
- 5) No data on progestins inducing migraine

## Conclusions

In conclusion, contraceptive counseling in migraine should take into account the risk-benefit profile of the individual woman before prescribing CHCs. In order to reduce potential vascular risks, recommendations should be a main point of guidance for prescribers. Progestogen-only contraception is a safer option in MA and eventually in MO with additional risk factors. Given preliminary evidences of a positive effect of the progestin-only pill desogestrel 75 µg on MA and MO in many, but not all women, further prospective trials have to be performed to confirm that progestogen-only contraception may be a better option for the management of both migraine and birth control. Differences between MA and MO should also be taken into account in further studies.

## Competing interests

Dr. Rossella E. Nappi has had financial relationships (lecturer, member of advisory boards, and/or consultant) with Bayer Pharma, Eli Lilly, Gedeon Richter, HRA Pharma, MSD, Novo Nordisk, Pfizer Inc., Shionogi Limited, Teva/Theramex. Dr. Gabriele S. Merki-Feld has had financial relationships (lecturer, member of advisory boards) with Bayer Pharma and MSD.

## Authors' contributions

Conception and design: REN, GSM. Acquisition of data: ET, AP. Analysis and interpretation of data: REN, MV, GSM. Drafting the article: REN, MV, GSM. Revising it for intellectual content: REN, MV, GSM. Final approval of the completed article: REN, REN, GSM, ET, AP, MV. All authors read and approved the final manuscript.

## Author details

<sup>1</sup>Research Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, IRCCS S. Matteo Foundation, Pavia, Italy. <sup>2</sup>Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Pavia, Italy. <sup>3</sup>Clinic for Reproductive Endocrinology, University Hospital Zürich, Zürich, Switzerland. <sup>4</sup>Headache Science Center - National Neurological Institute C. Mondino, Pavia, Italy. <sup>5</sup>Research Center for Reproductive Medicine, Unit of Obstetrics and Gynecology, IRCCS Policlinico 'San Matteo', Piazzale Golgi 2, 27100, Pavia, Italy.

Received: 9 June 2013 Accepted: 28 July 2013

Published: 1 August 2013

## References

1. Bigal ME, Lipton RB (2009) The epidemiology, burden, and comorbidities of migraine. *Neurol Clin* 27:321–334
2. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D et al (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 380:2163–2196
3. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, AMPP Advisory Group (2007) Migraine prevalence, disease burden, and the need for preventive therapy. *Neurology* 68:343–349
4. Lj S, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA (2007) The global burden of headache: a documentation of headache prevalence and disability worldwide. *Cephalalgia* 27:193–210
5. Stewart WF, Wood C, Reed ML, Roy J, Lipton RB, AMPP Advisory Group (2008) Cumulative lifetime migraine incidence in women and men. *Cephalalgia* 28:1170–1178
6. Nappi RE, Berga SL (2010) Migraine and reproductive life. *Handb Clin Neurol* 97:303–322
7. Mosher WD, Jones J (2010) Use of contraception in the United States: 1982–2008. *Vital Health Stat* 23(29):1–44
8. Skouby SO (2010) Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. *Eur J Contracept Reprod Health Care* 15:S42–S53
9. Johnson S, Pion C, Jennings V (2013) Current methods and attitudes of women towards contraception in Europe and America. *Reprod Health* 10:7
10. Maguire K, Westhoff C (2011) The state of hormonal contraception today: established and emerging noncontraceptive health benefits. *Am J Obstet Gynecol* 205:S4–S8
11. Shulman LP (2011) The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives. *Am J Obstet Gynecol* 205:S9–S13
12. Sitruk-Ware R, Nath A, Mishell DR Jr (2013) Contraception technology: past, present and future. *Contraception* 87:319–330
13. Calhoun A (2012) Combined hormonal contraceptives: is it time to reassess their role in migraine? *Headache* 52:648–660
14. Loder EW, Buse DC, Golub J (2005) Headache and combination estrogen-progestin oral contraceptives: integrating evidence, guidelines, and clinical practice. *Headache* 45:224–231
15. MacGregor EA (2007) Migraine and use of combined hormonal contraceptives: a clinical review. *J Fam Plann Reprod Health Care* 33:159–169
16. Steenland MW, Zapata LB, Brahmi D, Marchbanks PA, Curtis KM (2013) Appropriate follow up to detect potential adverse events after initiation of select contraceptive methods: a systematic review. *Contraception* 87:611–624
17. Massiou H, MacGregor EA (2000) Evolution and treatment of migraine with oral contraceptives. *Cephalalgia* 20:170–174
18. Aegidius K, Zwart JA, Hagen K, Schei B, Stovner LJ (2006) Oral contraceptives and increased headache prevalence: the Head-HUNT Study. *Neurology* 66:349–353
19. Granella F, Sances G, Pucci E, Nappi RE, Ghiotto N, Nappi G (2000) Migraine with aura and reproductive life events: a case control study. *Cephalalgia* 20:701–707
20. Curtis KM, Chrisman CE, Peterson HB, WHO Programme for Mapping Best Practices in Reproductive Health (2002) Contraception for women in selected circumstances. *Obstet Gynecol* 99:1100–1112
21. Loder EW, Buse DC, Golub JR (2005) Headache as a side effect of combination estrogen-progestin oral contraceptives: a systematic review. *Am J Obstet Gynecol* 193:636–649
22. Tassorelli C, Greco R, Allena M, Terreno E, Nappi RE (2012) Transdermal hormonal therapy in perimenstrual migraine: why, when and how? *Curr Pain Headache Rep* 16:467–473
23. De Leo V, Scolaro V, Musacchio MC, Di Sabatino A, Morgante G, Cianci A (2011) Combined oral contraceptives in women with menstrual migraine without aura. *Fertil Steril* 96:917–920
24. Nappi RE, Terreno E, Sances G, Martini E, Tonani S, Santamaria V, Tassorelli C, Spinillo A (2013) Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM). *Contraception*. doi:10.1016/j.contraception.2013.02.001, Epub ahead of print
25. Sulak P, Willis S, Kuehl T, Coffee A, Clark J (2007) Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. *Headache* 47:27–37
26. Calhoun A, Ford S, Pruitt A (2012) The impact of extended-cycle vaginal ring contraception on migraine aura: a retrospective case series. *Headache* 52:1246–1253
27. MacGregor EA (2013) Contraception and headache. *Headache* 53:247–276
28. Etrninan M, Takkouche B, Isorna FC, Samii A (2005) Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. *BMJ* 330:63–65
29. Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T (2009) Migraine and cardiovascular disease: systematic review and meta-analysis. *BMJ* 339:b3914
30. Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S (2010) Migraine headache and ischemic stroke risk: an updated meta-analysis. *Am J Med* 123:612–624
31. Sacco S, Ricci S, Carolei A (2012) Migraine and vascular diseases: a review of the evidence and potential implications for management. *Cephalalgia* 32:785–795
32. Scher AI, Terwindt GM, Picavet HS, Verschuren WM, Ferrari MD, Launer LJ (2005) Cardiovascular risk factors and migraine: the GEM population-based study. *Neurology* 64:614–620
33. Sacco S, Ricci S, Degan D, Carolei A (2012) Migraine in women: the role of hormones and their impact on vascular diseases. *J Headache Pain* 13:177–189
34. Gillum LA, Mamidipudi SK, Johnston SC (2000) Ischemic stroke risk with oral contraceptives: a meta-analysis. *JAMA* 284:72–78
35. Allais G, Gabellari IC, De Lorenzo C, Mana O, Benedetto C (2009) Oral contraceptives in migraine. *Expert Rev Neurother* 9:381–393
36. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C (2009) Hormonal contraception and risk of venous thromboembolism: national follow-up study. *BMJ* 339:b2890
37. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E (2011) Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. *BMJ* 343:d6423
38. Lidegaard Ø, Nielsen LH, Skovlund CW, Løkkegaard E (2012) Venous thrombosis in users of non-oral hormonal contraception: follow-up study. *Denmark* 2001–10 344:e2990
39. Sitruk-Ware R (2008) Pharmacological profile of progestins. *Maturitas* 61:151–157
40. Tchaikovski SN, Rosing J (2010) Mechanisms of estrogen-induced venous thromboembolism. *Thromb Res* 126:5–11
41. Dinger JC, Heinemann LAJ, Kuhl-Habich D (2007) The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on Oral Contraceptives based on 142,475 women-years of observation. *Contraception* 75:344–354
42. Dinger J, Pineda AA (2012) Risk of VTE in users of an etonogestrel-containing vaginal ring combined oral contraceptives. Abstract presented at the 60th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG). , San Diego, CA, USA
43. Sidney S, Cheetam TC, Connel FA, Ouellet-Hellstrom R, Graham DJ, Davis D, Sorel M, Quesenberry CP Jr, Cooper WO (2013) Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. *Contraception* 87:93–100
44. Bitzer J, Amy JJ, Beerthuisen R, Birkhäuser M, Bombas T, Creinin M, Darney PD, Vicente LF, Gemzell-Danielsson K, Imthurn B, Jensen JT, Kaunitz AM, Kubba A, Lech MM, Mansour D, Merki G, Rabe T, Sedlecki K, Serfaty D, Seydoux J, Shulman LP, Sitruk-Ware R, Skouby SO, Szarewski A, Trussell J, Westhoff C (2013) Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism. *Eur J Contracept Reprod Health Care* 18:143–147
45. Heinemann LAJ, Dinger JC (2007) Range of published estimates of venous thromboembolism incidence in young women. *Contraception* 75:328–336
46. World Health Organization (2010) Medical Eligibility for Contraceptive Use (4th edn)
47. Faculty of Sexual and Reproductive Healthcare UK Medical Eligibility Criteria for Contraceptive Use – November 2009. Revised May 2010
48. Burke AE (2011) The state of hormonal contraception today: benefits and risks of hormonal contraceptives: progestin-only contraceptives. *Am J Obstet Gynecol* 205:S14–S17
49. McCann MF, Potter LS (1994) Progestin-only oral contraception: a comprehensive review. *Contraception* 50:S1–S195
50. Collaborative Study Group on the Desogestrel-Containing Progestogen-Only Pill (1998) A double-blind study comparing the contraceptive efficacy,

- acceptability and safety of two progestogen-only pills containing desogestrel 75 µg/day and levonorgestrel 30 µg/day. *Eur J Contracep Reprod Health Care* 3:169–178
51. Backman T (2004) Benefit-risk assessment of the levonorgestrel intrauterine system in contraception. *Drug Saf* 27:1185–1204
  52. Power J, French R, Cowan F (2007) Subdermal implantable contraceptives versus other forms of reversible contraceptives or other implants as effective methods of preventing pregnancy. *Cochrane Database Syst Rev*:CD001326
  53. Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI (2012) Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. *BMJ* 345:e4944
  54. Chakhtoura Z, Canonico M, Gompel A, Thalabard JC, Scarabin PY, Plu-Bureau G (2009) Progestogen-only contraceptives and the risk of stroke: a metaanalysis. *Stroke* 40:1059–1062
  55. Kelman L (2004) The aura: a tertiary care study of 952 migraine patients. *Cephalalgia* 24:728–734
  56. Jensen JT, Trussell J (2012) Communicating risk: does scientific debate compromise safety. *Contraception* 86:327–329
  57. Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N (2012) Thrombotic stroke and myocardial infarction with hormonal contraception. *N Engl J Med* 366:2257–2266
  58. Somerville BW (1972) The role of estradiol withdrawal in the etiology of menstrual migraine. *Neurology* 22:355–365
  59. Somerville BW (1972) Estrogen-withdrawal migraine. II. Attempted prophylaxis by continuous estradiol administration. *Neurology* 25:245–250
  60. Greco R, Tassorelli C, Mangione AS, Smeraldi A, Allena M, Sandrini G, Nappi G, Nappi RE (2013) Effect of sex and estrogens on neuronal activation in an animal model of migraine. *Headache* 53:288–296
  61. Bolay H, Berman NE, Akcali D (2011) Sex-related differences in animal models of migraine headache. *Headache* 51:891–904
  62. Martin VT, Behbehani M (2006) Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis—part i. *Headache* 46:3–23
  63. Jayaraman A, Pike CJ (2009) Progesterone attenuates oestrogen neuroprotection via downregulation of oestrogen receptor expression in cultured neurones. *J Neuroendocrinol* 21:77–81
  64. Eikermann-Haerter K, Kudo C, Moskowitz MA (2007) Cortical spreading depression and estrogen. *Headache* 47:S79–S85
  65. Endrikat J, Gerlinger C, Richard S, Rosenbaum P, Düsterberg B (2011) Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide. *Contraception* 84:549–557
  66. Glasier A (2002) Implantable contraceptives for women: effectiveness, discontinuation rates, return of fertility, and outcome of pregnancies. *Contraception* 65:29–37
  67. Organization WH (1978) Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: norethisterone oenanthate and medroxyprogesterone acetate. 2. Bleeding patterns and side effects. *Contraception* 17:395–406
  68. Somerville B, Carey M (1970) The use of continuous progestogen contraception in the treatment of migraine. *Med J Aust* 1:1043–1045
  69. Nappi RE, Sances G, Allais G, Terreno E, Benedetto C, Vaccaro V, Polatti F, Facchinetti F (2011) Effects of an estrogen-free, desogestrel-containing oral contraceptive in women with migraine with aura: a prospective diary-based pilot study. *Contraception* 83:223–228
  70. Merki-Feld GS, Imthurn B, Langner R, Sandor PS, Gantenbein AR (2013) Headache frequency and intensity in female migraineurs using desogestrel-only contraception: a retrospective pilot diary study. *Cephalalgia* 33:340–346
  71. Rice C, Killick S, Hickling D, Coelingh Bennink H (1996) Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different doses. *Hum Reprod* 11:737–740
  72. Merki-Feld GS, Seifert B, Merki LL, Agosti R, Gantenbein AR (2013) Desogestrel-only contraception reduces headache frequency and improves quality of life in female migraineurs. *Eur J Contracep Reprod Health Care*, in press

doi:10.1186/1129-2377-14-66

**Cite this article as:** Nappi *et al.*: Hormonal contraception in women with migraine: is progestogen-only contraception a better choice? *The Journal of Headache and Pain* 2013 **14**:66.

**Submit your manuscript to a SpringerOpen<sup>®</sup> journal and benefit from:**

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► [springeropen.com](http://springeropen.com)